Cisplatin and Etoposide vs Paclitaxel in Advanced Breast Cancer
Author Information
Author(s): Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun Ş, Komurcu S, Erkisi M, Demirkazik A, Senler F C, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak S D
Primary Institution: Ibni Sina Hospital, Ankara University School of Medicine
Hypothesis
Is the combination of oral etoposide and cisplatin more effective than paclitaxel in treating advanced breast cancer patients pretreated with anthracyclines?
Conclusion
The combination of oral etoposide and cisplatin is more effective than paclitaxel in improving response rates and overall survival in patients with advanced breast cancer who have been pretreated with anthracyclines.
Supporting Evidence
- The response rate in the EoP arm was significantly higher at 36.3% compared to 22.2% in the paclitaxel arm.
- Median overall survival was longer in the EoP arm at 14 months compared to 9.5 months in the paclitaxel arm.
- Time to progression was significantly longer in the EoP arm at 5.5 months versus 3.9 months for paclitaxel.
Takeaway
This study found that a combination of two drugs, cisplatin and etoposide, works better than another drug called paclitaxel for treating certain breast cancer patients.
Methodology
This was a prospective randomised nonblinded multicentre phase III study comparing EoP and paclitaxel in patients with advanced breast cancer.
Limitations
The study did not assess quality of life.
Participant Demographics
Patients aged 18-70 with advanced breast cancer, pretreated with anthracyclines.
Statistical Information
P-Value
0.038
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website